Effect of fibrate treatment on liver function tests in patients with the metabolic syndrome

SpringerPlus

Table 4 Association between baseline factors and change in ALP following fibrate treatment

Model 1: Linear regression analysis with change in ALP as the dependent variable and the following as independent variables in separate analyses
	n	Co-efficient	95% C.I.	p-value
Pre-fibrate GGT	118	−0.02	−0.10- –0.002	0.04
Pre-fibrate ALP	118	−0.38	−0.48- –0.28	<0.001
Treatment duration	117	6.36	0.92-11.81	0.022
Statin treatment	118	6.63	0.75-12.5	0.028
Model 2: Multiple regression analysis with change in ALP as the dependent variable and the following as independent variables in single analysis
	n	Co-efficient	95% C.I.	p-value
Pre-fibrate GGT	117 (r² = 0.33)	0	−0.04-0.04	0.96
Pre-fibrate ALP		0.36	0.26-0.47	<0.001
Treatment duration		−4.56	−9.18-0.07	0.054
Statin treatment		2.00	−3.08-7.08	0.44

Age, gender, diabetes, pre-fibrate lipids (TC, TG & HDL-C), pre-fibrate ALT, pre-fibrate creatinine, changes in lipids (TC, TG & HDL-C) were not significantly associated with changes observed in ALP following fibrate treatment.